Weleff J

Faculty of Medicine and Dentistry, Department of Psychiatry, University of Alberta, Edmonton, Canada.

15 papers · 3 preprints · ORCID

ArticleKetamine

Ketamine Use Disorder and Entrenchment of Delusional Beliefs: A Case Report.

Yang SS, Goud R, Weleff J

Europe PMC2026
ArticleKetamine

Effects of psychedelics on opioid use disorder: a scoping review of preclinical studies

Pulido-Saavedra A, Oliva HNP, Prudente TP +7

Europe PMC2025
ArticleLSD

Who Keeps Using Lysergic Acid Diethylamide? Correlates of Past-Year Use in People Who Initiated Use at least Five Years Ago.

Barnett BS, Anand A, Weleff J +2

Europe PMC2026
ArticlePsychedelics

Psychiatric Residents' Perspectives on Psychedelics and Psychedelic Assisted Therapy.

Barnett BS, Arakelian M, Weleff J +4

Europe PMC2025
ArticleLSD

Perceived Availability of Lysergic Acid Diethylamide in the United States from 2015 to 2019.

Barnett BS, Anand A, Dewey EN +2

Europe PMC2026
ArticlePsilocybin

The therapeutic effects of psychedelics for opioid use disorder: A systematic review of clinical studies.

Weleff J, Pulido-Saavedra A, Aghaei AM +8

Europe PMC2025
ArticleKetamine

Effects of psychedelics on opioid use disorder: a scoping review of preclinical studies.

Pulido-Saavedra A, Oliva HNP, Prudente TP +7

Europe PMC2025
ArticleLSD

Perceived Risk of Trying Lysergic Acid Diethylamide in the United States from 2015 to 2019: Are Americans Assessing Lysergic Acid Diethylamide's Risk Profile More Favorably?

Barnett BS, Anand A, Dewey EN +4

Europe PMC2024
ArticlePsychedelics

From taboo to treatment: The emergence of psychedelics in the management of pain and opioid use disorder.

Weleff J, Nunes JC, Costa GPA +3

Europe PMC2024
ArticlePsilocybin

American Psychiatrists' Opinions About Classic Hallucinogens and Their Potential Therapeutic Applications: A 7-Year Follow-Up Survey.

Barnett BS, Arakelian M, Beebe D +5

Europe PMC2024
ArticlePsilocybin

Editorial: Psychedelics as treatments for substance use disorders: exploring therapeutic potential, risks, underlying mechanisms of action, and implementation challenges.

Barnett BS, Bassir Nia A, Sackett NB +1

Europe PMC2023
ArticlePsilocybin

Three Cases of Reported Improvement in Microsmia and Anosmia Following Naturalistic Use of Psilocybin and LSD.

Kovacevich A, Weleff J, Claytor B +1

Europe PMC2023
ArticleKetamine

Developing non-opioid therapeutics to alleviate pain among persons with opioid use disorder: a review of the human evidence.

Oliveira D, Fontenele R, Weleff J +2

Europe PMC2023
PreprintLSD

Perceived risk of LSD use in the United States from 2015-2019: Are Americans assessing LSD’s risk profile more favorably?

Barnett BS, Anand A, Dewey EN +3

Europe PMC2023
PreprintLSD

LSD use in the United States: Examining user demographics and their evolution from 2015-2019

Weleff J, Anand A, Dewey EN +1

Europe PMC2022
ArticlePsilocybin

Bibliometric Analysis of Academic Journal Articles Reporting Results of Psychedelic Clinical Studies.

Weleff J, Akiki TJ, Barnett BS

Europe PMC2023
PreprintPsilocybin

Bibliometric Analysis of Academic Journal Articles Reporting Results of Psychedelic Clinical Studies

Weleff J, Akiki TJ, Barnett BS

Europe PMC2021
ArticlePsilocybin

United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006-2020.

Barnett BS, Parker SE, Weleff J

Europe PMC2022